【MIZUHO BANK x CIC Tokyo】Global Pitch Series #3: JAPANESE Life Science Startups to Go Global! | Peatixtag:peatix.com,2011:12023-01-15T09:03:51+09:00PeatixCIC Tokyo【MIZUHO BANK x CIC Tokyo】Global Pitch Series #3: JAPANESE Life Science Startups to Go Global!tag:peatix.com,2022:event-34002552022-12-16T08:00:00JST2022-12-16T08:00:00JSTMIZUHO bank and CIC Tokyo collaborate to have a series of the global pitch events to spot light wonderful Japanese startups and connect with global players including overseas investors and corporates. CIC Tokyo, one of the biggest innovation centre in Japan who are building an innovation ecosystem, and Mizuho Bank which provides support for fast-growing innovative companies, will collaborate and co-organise the event.
This event will feature leading startups in the life science sector that are driving the next generation of innovation in Japan. Japanese startups have a great technology which can be lead the world and create a better future. Life Science sector is a hot industry sector in Japan and also in global market and lots of great and exciting startups are coming up and growing rapidly. Japanese leading startups have a huge potential to play an important role globally.We invite 6 Japanese startups to give pitches and provide an opportunity to connect with global investors & corporate which will be a gateway for those leading startups to go global and expand their businesses to change the world!This will be a great opportunity for investors and overseas company to feel the forefront of innovation in Japan, so come join us and connect with them!
【EVENT INFO】
Date / Time：16th Dec, Friday 8:00 - 9:00 am JSTVenue： OnlineFee：FreeLanguage: English
【Time Table】
8:00 - 8:10 am JST Opening remarks
Masato Kaneda / General Manager of Innovative Startups Coordination Department, MizuhoBank, Ltd.
Dr. Michelle Ottey / CIC Philadelphia
[MC] Ayano Kagami / Community Development Lead, CIC Tokyo
8:10 - 8:58 am JST Startup Pitches!＜STARTUP>
Hiromu Ozaki, Takanori Takebe / CEO (Ozaki) and Founder (Takebe), EVA Therapeutics, Inc.
Hide Takahashi / CEO, PuREC Co., Ltd.
Yusaku Katada / CEO, Restore Vision
Asako Uchiyama / Chief Development Officer, Celaid Therapeutics Inc.
Hiroshi Sakai, Ph.D. / Chief Strategy Officer, aiwell
Tomoki Otani / Director, VC Cell Therapy
＜Commentator＞
Michelle Ottey / Managing Director, CIC Philadelphia,
Veenu Aishwarya / CEO and Founder of AUM Lifetech
8:58 - 9:00 am JST Closing RemareksMasaru Nagura / General Manager, CIC Tokyo
【Pitch Speakers】Hiromu Ozaki / CEO, EVA Therapeutics, Inc. Mr. Ozaki is an experienced pharma industry veteran with leadership roles in pharmaceutical/biotech companies including CEO of Biogen-Japan, Sosei-Japan and Astellas Pharma Canada. Quite recently Mr. Ozaki has been heavily involved in business development activities of bio-venture companies in Japan.[About EVA Therapeutics, Inc. ] EVA Therapeutics, Inc. is a startup bio-venture corporation with the vision to implement Dr. Takanori Takebe’s scientific approach to unlock new potential of existing organs in the body to supplement other lost organ functions. The EVA technology is the foundation of our company and its lead project, EVA101 is the intra-rectal delivery of a liquid form of O2 (oxygen) with perfluorocarbon. The product is in Phase 1a clinical trial in Japan in collaboration with Maruishi Pharma, well-established local acute care company. EVA Therapeutics, Inc is a certified spin-out venture from Tokyo Medical and Dental University.Takanori Takebe / Founder, EVA Therapeutics, Inc. Dr. Takanori Takebe is Scientific Founder of EVA Therapeutics Inc. He is a professor at Tokyo Medical and Dental University, Japan and jointly appointed as a Director of Commercial Innovation at Center for Stem Cell and Organoid Medicine (CuSTOM), Endowed Chair and Associate Professor at Cincinnati Children’s Hospital Medical Center, USA.Hide Takahashi / CEO, PuREC Co., Ltd.
Hide Takahshi joined PuREC in 2019 to lead the business of the company and became CEO in 2020. His various experience not only in bio-tech industry (Sucampo Pharmaceuticals in U.S. and Oncolys BioPharma in Japan) but also in banking industry(MUFG) and manufacturing industry (Toyota Motors) has helped the company to establish the solid business base as well as the recent series B finance for $5.4M. Hide had lived in Boston, New York and Bethesda (MD) in U.S. in total more than 10 years and obtained a MS degree from Massachusetts Institute of Technology.[About PuREC Co., Ltd. ] Since its inception in 2016, PuREC has established a proprietary purification method to obtain the extremely purified MSC (mesenchymal stem cells) called "REC" (Rapidly Expanding Cells) from human bone marrow. "REC" is currently used in two investigator-led clinical trials in Japan: 1) Ph-I/IIa for Hypophosphatasia at Shimane University, and 2) Ph-I/IIa for Lumber / Spinal Canal Stenosis at Hokkaido University.Yusaku Katada / CEO, Restore Vision President and Chief Executive Officer Dr. Yusaku Katada co-founded Restore Vision. Prior to founding Restore Vision, he led research in visual restoration gene therapy at the Department of Ophthalmology, Keio University School of Medicine, where he received his Ph.D. in Medical Science. He is also an ophthalmologist with 10 years of experience and has been in charge of the outpatient retinal degenerative diseases clinic at Keio University Hospital since 2019.[About Restore Vision] Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy for retinitis pigmentosa. In collaboration with the Keio University School of Medicine, we have a promising product with high sensitivity enabling patients to see even under low light conditions. It has proven to have competitive advantages at the pre-clinical stage, and we are currently working towards an early clinical data acquisition. Asako Uchiyama / Chief Development Officer, Celaid Therapeutics Inc. Asako joined Celaid in June 2021 and currently serves as the Chief Development Officer and General Manager of Business Development controlling product and business development in the US. Prior to Celaid, she was the Junior Director at a preclinical GLP facility where she established new lines of analyses and services for safety assessment of cell/gene therapy products as well as managed the team that provides contract studies to pharmaceutical companies. Her professional roles have ranged from research scientist for viral vector vaccines to manager of overseas business development in the area of vaccines for nasal delivery. [About Celaid Therapeutics Inc. ] Celaid Therapeutics was founded in Oct 2020 based on the core technology that enables ex vivo expansion of hematopoietic stem cells, which had been sought after for many years in the hematology field. Celaid is developing cord blood-derived allogeneic hematopoietic stem cell therapy products as an alternative to current stem cell transplantation. We aim to become the new standard for treatment of, and even cure for, hematological diseases.Hiroshi Sakai, Ph.D. / Chief Strategy Officer, aiwell Hiroshi received Ph.D in department of Chemistry and Biotechnology school of Engineering from the University of Tokyo. His major is molecular biology. After graduation, he joined a foreign pharmaceutical company and worked in the sales and marketing departments before joining Boston Consulting Group. He has experienced a wide range of projects, mainly in the healthcare industry, including new business formulation, business reform, M&A support, and mid-term management planning.He joined aiwell in January 2022.[About aiwel ] A certified Tokyo Institute of technology venture company, in 2018 it began joint research with Tokyo Institute of technology to advance the practical application of AI proteomics; in April 2019, it established a collaborative research center on campus at Tokyo Institute of technology .By promoting the social implementation of AI proteomics, the company is working to realize services that enable diagnostic support, remote medical care support, and drug discovery support based on AI image judgment before subjective symptoms of illness or injury appear or before serious illness or injury occurs. We are currently conducting joint research with various companies to promote the practical application, generalization, and social implementation of AI proteomics.Tomoki Otani / Director, VC Cell TherapyPhD in stem cell biology from University of Cambridge, Ex-Associate Partner at McKinsey&Company, Ex-R&D lead for immunotherapy startup[About VC Cell Therapy ] VC Cell Therapy is a clinical-stage company developing regenerative cell therapies for retinal degeneration diseases. Two assets are under development for global market - allogeneic iPS-derived retinal pigment epithelial cells and allogeneic iPS-derived photoreceptor cells. The company is differentiated as – (1) Making cell therapy available from 2023 in Japan leveraging an expedited regulatory pathway, (2) Clinically verified cell products already applied to ~10 patients without any major complications, (3) Optimized cell product formulation to enhance safety profile, and (4) Automated manufacturing using a humanoid robot ready for technical transfer【Commentators】Michelle Ottey / Managing Director, CIC Philadelphia,Veenu Aishwarya / CEO and Founder of AUM LifetechAn immigrant from India, Veenu Aishwarya is an innovator and a result-oriented biotechnology entrepreneur. He received his biomedical research training while working as a visiting scholar at the Perelman School of Medicine, University of Pennsylvania in Philadelphia. At AUM LifeTech, Mr. Aishwarya has been leading, developing, and strategizing applications of AUM LifeTech’s proprietary next-generation RNA Silencing FANA Antisense Oligonucleotide Technology (FANA ASO) for personalized medicine. Mr. Aishwarya has over 15 years of experience in discovery, optimization, and development of nucleic acids therapeutics. Mr. Aishwarya has invented several new medical applications of FANA ASO technology including the use of FANAs for cancer immunotherapy. Mr. Aishwarya has filed several patents on the use of FANA ASO technology for multiple research and therapeutic applications. Several of his inventions and products have shown significant commercial value in biomedical research and therapeutic development. Most recently, under Mr. Aishwarya’s leadership, AUM LifeTech was selected by the NIH as a part of the BIO Innovation Zone 2021. The Innovation Zone showcases NIH-funded small businesses and their cutting- edge healthcare technologies.In 2017, Mr. Aishwarya was recognized as Millennials to Watch in Life Sciences by the Philadelphia Business Journal. In 2018, he was recognized as one of the 2018 Health Care Innovators by the Philadelphia Business Journal. In 2019, Mr. Aishwarya was recognized as the Forty under 40 business leaders by the Philadelphia Business Journal. He is also an invited member of the Philadelphia Leadership Trust and recognized as a Business Influencer by the Philadelphia Business Journal in 2020. Most recently, Mr. Aishwarya was recognized as the 2021 Diversity Leaders in Business by the Philadelphia Business Journal.Mr. Aishwarya serves on the editorial board of Molecular Therapy – Nucleic Acids (Nature Publishing Group). He is a nominated member of the RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society. He is also a member of The American Association of Cancer Research, The American Society of Gene and Cell Therapy, The American Association for the Advancement of Science, The New York Academy of Sciences, and The International Society of Nucleosides, Nucleotides and Nucleic Acids. He was also selected for a young scientist award program by the Keystone Symposia. He has authored several research articles and invited book chapters in publications like BMC, Oxford, Elsevier and Springer. He serves a referee/reviewer at journals like – Journal of Molecular Biology (Elsevier), Oncogene (Nature Publishing Group), BMC Genomics, Molecular Therapy – Nucleic Acids (Nature Publishing Group) and Journal of Biomedical Research. Mr. Aishwarya has been invited, on several occasions, to write on leadership and entrepreneurship by Fortune Magazine.Mr. Aishwarya has also been a Milken Institute Assocaite. The Milken Institute is an independent economic think tank whose mission is to improve the lives and economic conditions of diverse populations in the United States and around the world by helping business and public policy leaders identify and implement innovative ideas for creating broad-based prosperity. The Milken Institute Associates provides a vital link between the worlds of business, government, economics and philanthropy.Mr. Aishwarya has been a frequently invited delegate at highly regarded global interdisciplinary forums like Forbes Health Care Summit, Fortune Brainstorm TECH, JP Morgan Healthcare conference, Milken Institute Global Conference, Partnering for Cures (Faster cures) and TEDMED. 【Moderators】Masato Kaneda / General Manager of Innovative Startups Coordination Department, MizuhoBank, Ltd. Masato Kaneda began his career at Mizuho Bank, and now, as General Manager, leads the Innovative Startups Coordination Department, a company-wide initiative leading innovation clients including startups by providing different types solutions such as loan, transaction banking, investment by leveraging in-house VC, running acceleration programs, coordination between large companies and startups, supporting IPO, after IPO finance and M&A through Mizuho’s investment banking arm.Masaru Nagura / General Manager, CIC Tokyo Masaru comes to CIC with a background in multiple sectors including government, business consulting, and investment. At the Japanese Ministry of Education, Culture, Sports, Science, and Technology, he oversaw governmental programs for startups and entrepreneurship education. In 2015, he began research on innovation ecosystems through MIT’s system design and management program, and during this time in Cambridge, he supported CIC’s international expansion to Japan. Upon returning to Japan, Masaru worked at a consulting and venture capital firm, focusing on technology-driven innovation, until he rejoined CIC in 2020.Ayano Kagami, Ph.D. / Community Development Lead, CIC JapanAyano comes to CIC with passion to develop a biotech/healthcare startup ecosystem in Japan. She received Ph.D. in molecular biology from University of Tokyo before joining Ministry of Education, Culture, Sports, Science and Technology (MEXT). At MEXT, she worked on policy making in the life science field and medicine and was assigned to design the Japan Agenscy for Medical Research and Development (AMED). In 2017, she started to study at MIT’s system design and management program and researched about the deifference of startup ecosystems especially in life science field between Cambridge/Boston and several cities in the U.S. and Japan. After returning Japan, she worked on the science, technology and innovation policy at Cabinet office and on the reesarch and on the research and dvelopment project for nuclear fusion field until she joined CIC Japan in 2021.
【About Mizuho Bank Company】
Mizuho Bank provides essential support such as managerial knowledge, business performance know-how, business expansion opportunity, and fund raising, for fast-growing innovative companies* by fully utilizing its core capabilities such as Mizuho Financial Group’s network, delivery of financial services, and consulting.Since the start of “M’s Salon”, a membership service for innovative companies, in 2017, the number of membership companies has exceeded 3,600.The Bank contributes to the rapid growth of innovative companies through establishment of about 60 Support Companies centered on large leading Japanese enterprises, 40 Mentors who are experts in the fields of management and business performance as well as business matching opportunities and hosting various seminars with mainly venture capitals with close relationships with the Bank.*Start-ups that operate innovative businesses such as providing products or services using leading-edge technologyMizuho Bank: https://www.mizuhogroup.com/bankM’s Saoln : https://www.mizuhobank.co.jp/corporate/b_support/ms_salon/special/index.html
【About CIC Tokyo】
CIC TokyoIn October 2020, CIC Tokyo launched as CIC's first location in Japan and as Japan's largest innovation center. CIC Tokyo offers shared and private workspace, which can accommodate around 300 companies with a focus on global startups aiming for rapid growth, as well as other innovation companies and organizations. In addition, CIC Tokyo builds an innovation community in the energy and environment field to support innovators in the field locally and globally. Also, CIC Tokyo provides supports to non-Japanese startups to establish their business in Japan.Updatestag:peatix.com,2022-12-15 03:41:162022-12-15 03:41:16イベント詳細情報を更新しました。 Diff#1303798Updatestag:peatix.com,2022-12-15 01:21:282022-12-15 01:21:28イベント詳細情報を更新しました。 Diff#1303726Updatestag:peatix.com,2022-12-15 01:12:492022-12-15 01:12:49イベント詳細情報を更新しました。 Diff#1303723Updatestag:peatix.com,2022-12-13 03:20:462022-12-13 03:20:46イベント詳細情報を更新しました。 Diff#1303073Updatestag:peatix.com,2022-12-13 03:18:212022-12-13 03:18:21イベント詳細情報を更新しました。 Diff#1303071Updatestag:peatix.com,2022-12-12 06:24:322022-12-12 06:24:32イベント詳細情報を更新しました。 Diff#1302730Updatestag:peatix.com,2022-12-12 06:18:302022-12-12 06:18:30イベント詳細情報を更新しました。 Diff#1302728Updatestag:peatix.com,2022-12-12 03:04:002022-12-12 03:04:00イベント詳細情報を更新しました。 Diff#1302647Updatestag:peatix.com,2022-12-09 01:18:332022-12-09 01:18:33イベント詳細情報を更新しました。 Diff#1301616Updatestag:peatix.com,2022-12-08 08:38:472022-12-08 08:38:47イベント詳細情報を更新しました。 Diff#1301425Updatestag:peatix.com,2022-12-08 08:34:122022-12-08 08:34:12イベント詳細情報を更新しました。 Diff#1301422Updatestag:peatix.com,2022-12-08 08:22:132022-12-08 08:22:13イベント詳細情報を更新しました。 Diff#1301420Updatestag:peatix.com,2022-12-08 00:41:592022-12-08 00:41:59イベント詳細情報を更新しました。 Diff#1301122Updatestag:peatix.com,2022-12-08 00:39:582022-12-08 00:39:58イベント詳細情報を更新しました。 Diff#1301121Updatestag:peatix.com,2022-12-07 05:43:352022-12-07 05:43:35イベント詳細情報を更新しました。 Diff#1300798Updatestag:peatix.com,2022-12-07 02:06:032022-12-07 02:06:03イベント詳細情報を更新しました。 Diff#1300693Updatestag:peatix.com,2022-12-07 01:17:322022-12-07 01:17:32イベント詳細情報を更新しました。 Diff#1300664Updatestag:peatix.com,2022-12-06 09:19:232022-12-06 09:19:23イベント詳細情報を更新しました。 Diff#1300487Updatestag:peatix.com,2022-12-05 11:03:582022-12-05 11:03:58イベント詳細情報を更新しました。 Diff#1300161